News Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 08/05/2026 BST			5-day change	1st Jan Change
5.160 ^EUR	-1.90%		+6.39%	-24.56%

03-25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-20	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment	MT

All News

Mentions Relevance

05-08	Hyloris Pharmaceuticals : Regulated Information Hyloris’ Annual General Shareholders Meeting on June 9, 2026 ENGLISH VERSION	PU
04-30	Hyloris Pharmaceuticals : releases Annual Report 2025	PU
04-30	Hyloris Pharmaceuticals : Regulated Information Hyloris releases Annual Report 2025 ENGLISH VERSION	PU
03-26	Consolidated Results 2025 - Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position: a year of bold moves and breakthrough milestones	PU
03-25	Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-19	Hyloris Pharmaceuticals : Inside Information Hyloris Provides Update on FDA Review of Valacyclovir for Oral Suspension ENGLISH VERSION	PU
02-19	Hyloris Pharmaceuticals : Provides Update on FDA Review of Valacyclovir for Oral Suspension	PU
02-02	Hyloris Pharmaceuticals : Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings	PU
01-20	Hyloris Pharmaceuticals Partners With Orion to Commercialize Gastric Acid Treatment	MT
01-19	Hyloris Pharmaceuticals : Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets	PU
01-19	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Strategic Partnership with Orion for its RTU Pantoprazole IV in European Markets ENGLISH VERSION	PU
12-31	Hyloris Secures European, Turkish License for ArborMed's Rare Disease Drug	MT
12-30	Hyloris Pharmaceuticals : Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed	PU
12-30	Hyloris Pharmaceuticals obtains exclusive license rights in Europe & Turkey from Arbormed for its Wilson's disease therapy	RE
12-30	Hyloris Pharmaceuticals, Rosemont Pharmaceuticals Sign US Licensing, Supply Deal for Atomoxetine Oral Solution	MT
12-29	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSION	PU
12-29	Hyloris announces partnership with Rosemont Pharmaceuticals for atomoxetine oral solution in the U.S.	RE
12-12	Hyloris Pharmaceuticals, Wake Forest University to Develop Rare Skin Disorder Therapy	MT
12-11	Hyloris Pharmaceuticals : Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder	PU
12-11	Hyloris Pharmaceuticals : Non-Regulated Information Hyloris Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder ENGLISH VERSION	PU
11-19	Hyloris Pharmaceuticals Appoints Co-CEO as Sole Chief Executive	MT
11-19	Hyloris Pharmaceuticals : Board of Directors appoints Stijn Van Rompay as CEO	PU
11-19	Hyloris Pharmaceuticals : Inside Information Hyloris Board of Directors appoints Stijn Van Rompay as CEO ENGLISH VERSION	PU
11-14	Hyloris Pharmaceuticals : Announces Positive Clinical Study Results for IV Aspirin	PU
11-14	Hyloris Pharmaceuticals : Inside Information Hyloris Announces Positive Clinical Study Results for IV Aspirin ENGLISH VERSION	PU